(Q38037491)

27 August 2017

Emerging immunotherapies for renal cell carcinoma (English)

1 reference

27 August 2017

1 reference

B Escudier

1

1 reference

27 August 2017

1 September 2012

1 reference

27 August 2017

1 reference

27 August 2017

23 Suppl 8

1 reference

27 August 2017

viii35-40

1 reference

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

27 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Treatment of metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Sequential therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Immunotherapy of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Immunotherapeutic strategies in kidney cancer--when TKIs are not enough

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

[Adjuvant autologous tumour cell vaccination in patients with renal cell carcinoma. Overall survival analysis with a follow-up period in excess of more than 10 years].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and alpha-IFN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Soluble human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS261

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS261

1 reference

27 August 2017

1 reference

PubMed ID

22918926